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INTRODUCTION 
Arrhythmias are disturbance of either cardiac rhythm 
generation or conduction. Amiodarone is frequently 
used drug in arrhythmias. It is first line of treatment 
for ventricular tachycardia,1 particularly effective in 
supraventicular tachycardia like atrial fibrillation. 
Adverse effect of amiodarone includes cardiac and 
extra cardiac effects. Hormonal disturbance such as 
hyper/hypo thyroids can manifest due to high iodine 
content in the drug. Abnormal liver function, 
photodermatitis, corneal deposit, bradycardia, heart 
block with pre-existing AV node pathology, 
vasodilation can be seen on this drug administration.2 
There are some rare adverse effects of amiodarone 
such as Pulmonary fibrosis and syndrome of 
inappropriate diuretic hormone (SIADH). We report 
a patient who developed multiple complications after 
amiodarone therapy which included hypothyroidism, 
hyponatremia, increased bilirubin. Extent of 
relationship between a drug and a suspected reaction 
is established by Causality assessment. It is often 
difficult to decide if an adverse clinical event is 
anadverse drug reaction (ADR) or due to 
deterioration in the primary clinical condition.  
 
Furthermore, if it is an ADR, then which drug caused 
it, as many patients are on multiple new medications 
when ill, especially if hospitalized. Algorithms being 
structured systems specifically designed for 
establishing causal relationship of drug to an ADR, 
make more objective decision on causality 
assessment. A number of algorithms or decision aids 
have been published for casualty assessment 
including     the     Jones    ‘algorithm,    the    Naranjo  
 
 
algorithm, the Yale algorithm, the Kerch algorithm, 
the Begaud  algorithm, the Adverse Drug Reactions 
Advisory Committee (ADRAC), the WHO UMC, and 
a newer quantitative approach Algorithm.3 For 
present study, we have established causality 
relationship of ADRs with drugs using Naranjo scale. 
 
CASE REPORT 
A spontaneously reported case of 52 year old male 
presented with abdominal discomfort, palpitation, 
tiredness and weakness while undergoing treatment 
with amiodarone, atorvastatin, metoprolol, aspirin 
and prasugrel. 
 
Patient had underwent Percutaneous transluminal 
coronary angioplasty (PTCA) in Left anterior 
descending artery (LAD) one and a half month back. 
His hospital stay was uneventful. He was discharged 
and was prescribed atorvastatin, amlodipine, aspirin 
and prasugrel.  
 
Two days after discharge, patient reported to hospital 
with complaint of diffuse chest pain which was dull 
and non-radiating, associated with palpitation along 
with dyspnea (grade NHYA 2). He was diagnosed 
with atrial fibrillation and was given amiodarone 
intravenous(i.v.) infusion to control the arrhythmia. 
Patient was prescribed oral amiodarone (200 mg) 
along with metoprolol, aspirin and prasugrel on 
discharge from hospital. Dose of amiodarone was 
reduced to 100 mg on follow up after 1 month. 
 
One  and a  half  month  later,  patient presented  with 
 
K 
Amiodarone Toxicity: A Case Report 
CASE REPORT 
 
A 
B 
S 
T 
R 
A 
C 
T 
ISSN: 2456-8090 (online) 
DOI: 10.26440/ihrj.v2i10.193  
HINA LAL1, JATINDER SINGH*2, VIJAY KUMAR3, ENA BHAJNI4, VIJAY K. SEHGAL5 
QR CODE 
 
Amiodarone is one of the commonly used drug in arrhythmias. It is first line of treatment for ventricular tachycardia particularly in 
treatment of supraventicular tachycardia like atrial fibrillation. Amiodarone has a wide range of adverse effects ranging from 
endocrine to cardiac system. A case of raised thyroid stimulating Hormone (TSH)  with amiodarone was reported in our Adverse 
drug  monitoring centre (AMC), in which several other adverse events such as raised raised billirubin and hyponatremia were 
present. Patient was treated with thyroxine while amiodarone along with atorvastatin and metoprolol were withdrawn. We present 
a case who developed subclinical hypothyroidism, electrolyte imbalance and liver dysfunction with amiodarone therapy. 
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abdominal discomfort, palpitation, tiredness and 
weakness. Patients thyroid stimulating hormone 
(TSH) was raised (13.72 uIU/ml; normal range: 0.35-
5.5 uIU/ml), bilirubin was raised (2.8 mg/dl; normal 
range: 0-1 mg/dl) and patient had hyponatremia (125 
mmol/L; normal range: 135-145 mmol/L) and 
hypokalemia (3.4 mmol/L; normal range: 3.6-5.0 
mmol/L). It was accompanied by proteinuria 
(350mg/24 hr; normal range: 40-150 mg/24 hours). He 
was admitted to hospital after 2 days where his 
sodium(Na+) level further decreased to 109mmol/L 
and his anti-thyroid peroxidase (anti TPO) antibodies 
came out to be 250 IU/ml (normal range: 60 IU/ml). 
He was treated will oral and i.v sodium and iv 
potassium, thyroxine (50 mcg) while amiodarone, 
atorvastatin and metoprolol were withdrawn. Patient 
was treated with aspirin, prasugrel, and simvastatin. 
Patient was regularly followed up for sodium and TSH 
level. There was a gradual decrease in TSH level and 
TSH was within normal limit (3.5uIU/ml) after 2 
months. The Na+ levels were still low (3.57mmol/ml), 
while the potassium levels came back to normal. 
 
The patient was non-smoker. He had history of 
hypertension and was treated with telmisartan for 10 
years. He was diagnosed with obstructive sleep apnea 
six months back and was on nocturnal CPAP since 
then. Patient had a single episode of increased TSH 
one year (7.90uIU/ml). His Anti TPO level was 70.9 
IU/ml. However, patient was always euthyroid, so no 
medication was started. During the investigation 
performed before PTCA patient had TSH within 
normal limit.  
 
DISCUSSION 
Amiodarone is a structural analogue of thyroid 
hormone. Being a highly lipophilic drug, it gets 
accumulated in many tissues and is slowly eliminated 
from the body. This may be reason for its prolonged 
adverse effects with late recovery.1 It contain 37 % 
iodine in its structure i.e. 200 mg iodine provides 75 
mg of iodine to the patient. This may lead to either 
hypo or hyperthyroidism as seen in case discussed 
above. This is seen especially in patients with 
underlying hashimoto’s disease or grave disease.4 The 
above case had one recorded episode of raised TSH 
and Anti TPO antibodies and was on amiodarone 
therapy, which may have predisposed him to 
development of sub clinical hypothyroidism as was 
evident with the increase in TSH levels and normal 
T3,T4 levels. 
Hyponatremia is a rare complication with 
amiodarone.5 Causality assessment of hyponatremia 
was probable for amiadarone, atorvastatin and 
metoprolol according to naranjo scale. In above case 
along with hyponatremia, patient had other 
electrolyte imbalance such as hypokalemia. 
Following Naranjo scale, causality assessment of 
hypokalemia is probable for amiodarone, atorvastatin 
and metoprolol.  Proteinuria seen in this case can be 
attributed to hypertension affecting kidney or the 
drugs given which was further investigated. Causal 
relationship of proteinuria was possible for 
amiodarone, atorvastatin and metoprolol according 
to naranjo causality assessment scale.   
 
Pulmonary fibrosisis the main concern in amiodarone 
toxicity as it may prove to be fatal.1 However, in our 
case no pulmonary changes were reported. Any 
hepatotoxic injury is indicated by raised liver enzyme 
such as Alkaline phosphatase (ALP), Aspartate 
transaminase (AST) etc. However, we only observed 
raised bilirubin in patient with normal liver enzyme. 
Increase in bilirubin may be due to amiodarone or 
atorvastatin. 
 
CONCLUSION  
Amiodarone, although a very effective tool in 
arrhythmia, should be used judiciously and patients 
should be monitored for thyroid, liver and electrolyte 
imbalance to detect any untoward event early during 
the therapy. 
 
Abbreviations: TSH-thyroid stimulating Hormone, 
SIADH-syndrome of inappropriate diuretic hormone, 
PTCA-Percutaneous transluminal coronary 
angioplasty, LAD- Left anterior descending artery, 
TPO-thyroid peroxidase. 
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